The Treatment-Resistant Hypertension therapeutics market space will experience significant changes owing to the launch of upcoming novel therapies and a robust pipeline of drugs in development to manage RHTN. However, the challenges of pricing and reimbursement and associated side effects are two major factors likely to influence the market success of the upcoming therapies.
DelveInsight’s “Treatment-Resistant Hypertension (RHTN) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Treatment-Resistant Hypertension market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Treatment-Resistant Hypertension market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Treatment-Resistant Hypertension (RHTN): An Overview
Treatment-resistant Hypertension (RHTN) is defined as uncontrolled blood pressure despite the use of ≥3 antihypertensive agents of different classes, including a diuretic, usually thiazide-like, a long-acting calcium channel blocker, or a blocker of the renin-angiotensin system, either an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angiotensin receptor blocker), at maximal or maximally tolerated doses.
The main treatment strategies adopted for treatment-resistant hypertension include both nonpharmacological and pharmacological interventions. Nonpharmacological interventions include lifestyle modifications, a DASH diet, reduced salt intake, restricted alcohol consumption, etc. Pharmacological interventions include withdrawal of interfering medication, optimization of diuretic therapy, mineralocorticoids, combination therapy, and the use of Spironolactone as the fourth agent for treating RHTN.
Treatment-Resistant Hypertension (RHTN) Market Key Facts
-
Treatment-resistant Hypertension (RHTN) market size in the seven major markets was over USD 13 billion in 2021.
-
The Treatment-resistant Hypertension (RHTN) prevalent cases in 7MM countries was ~16.4 million in 2021.
-
As per the estimates, the United States has the largest prevalent population of Treatment-resistant Hypertension.
-
Among the EU5 countries, Germany had the highest prevalent cases of Treatment-resistant Hypertension, followed by Italy and Spain. On the other hand, the UK had the lowest prevalent cases, with ~600k cases in 2021.
-
To meet the urgent need for novel medications to treat RHTN with different MoA, few promising therapies in development are firibastat (Quantum Genomics), aprocitentan (Idorsia Pharmaceuticals), CIN-107 (CinCor Pharma), IONIS-AGT-LRx (Ionis Pharmaceuticals), patiromer (Vifor Pharma), among others. Other promising therapies include device-based intervention, including renal denervation.
Treatment-Resistant Hypertension (RHTN) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Treatment-Resistant Hypertension market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Treatment-Resistant Hypertension market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Treatment-Resistant Hypertension (RHTN) Epidemiology Assessment
The disease epidemiology covered in the report provides historical and forecasted Treatment-resistant Hypertension (RHTN) symptoms epidemiology segmented as the Total Prevalent Cases, Gender-specific Cases, and Age-specific Cases.
The report includes the prevalent case scenario of Treatment-resistant Hypertension (RHTN) in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Treatment-Resistant Hypertension (RHTN) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Treatment-Resistant Hypertension market or expected to get launched during the study period. The analysis covers the Treatment-Resistant Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Treatment-Resistant Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Treatment-Resistant Hypertension Market Will Evolve by 2032 @
https://www.delveinsight.com/sample-request/treatment-resistant-hypertension-market
Treatment-Resistant Hypertension (RHTN) Therapeutics Analysis
As per DelveInsight, Treatment-resistant Hypertension (RHTN) market in 7MM is expected to grow steadily in the coming years owing to the launch of emerging therapies.
Some of the key companies in the Treatment-Resistant Hypertension (RHTN) Market include:
-
Idorsia Ltd
-
Janssen Biotech
-
Quantum Genomics SA
-
CinCor Pharma
-
Ionis Pharmaceuticals
-
Vifor Pharma
-
KBP Biosciences
And many more
Treatment-Resistant Hypertension (RHTN) drugs covered in the report include:
-
Aprocitentan: Idorsia Ltd/Janssen Biotech
-
CIN-107: CinCor Pharma
-
Firibastat (QGC001): Quantum Genomics SA
And many others
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @
https://www.delveinsight.com/sample-request/treatment-resistant-hypertension-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Treatment-Resistant Hypertension Competitive Intelligence Analysis
4. Treatment-Resistant Hypertension Market Overview at a Glance
5. Treatment-Resistant Hypertension Disease Background and Overview
6. Treatment-Resistant Hypertension Patient Journey
7. Treatment-Resistant Hypertension Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Treatment-Resistant Hypertension Treatment Algorithm, Current Treatment, and Medical Practices
9. Treatment-Resistant Hypertension Unmet Needs
10. Key Endpoints of Treatment-Resistant Hypertension Treatment
11. Treatment-Resistant Hypertension Marketed Products
12. Treatment-Resistant Hypertension Emerging Drugs and Latest Therapeutic Advances
13. Treatment-Resistant Hypertension Seven Major Market Analysis
14. Attribute Analysis
15. Treatment-Resistant Hypertension Market Outlook (In US, EU5, and Japan)
16. Treatment-Resistant Hypertension Access and Reimbursement Overview
17. KOL Views on the Treatment-Resistant Hypertension Market
18. Treatment-Resistant Hypertension Market Drivers
19. Treatment-Resistant Hypertension Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/treatment-resistant-hypertension-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Chronic Insomnia Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Chronic Insomnia Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/